New drug MDI-2517 put to the test in healthy volunteers
Knowledge-focused
Recruiting now
This early-stage study is testing whether the experimental drug MDI-2517 is safe in healthy adults aged 18 to 55. About 52 participants will receive either the drug or a placebo, and researchers will monitor for side effects, lab changes, and how the drug moves through the body. …
Phase: PHASE1 • Sponsor: MDI Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 01, 2026 15:57 UTC